Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers.

Cheung NK, Kushner BH, LaQuaglia MP, Kramer K, Ambros P, Ambros I, Ladanyi M, Eddy J, Bonilla MA, Gerald W.

Eur J Cancer. 1997 Oct;33(12):2117-20.

PMID:
9516865
2.

Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?

Ambros PF, Ambros IM, Strehl S, Bauer S, Luegmayr A, Kovar H, Ladenstein R, Fink FM, Horcher E, Printz G, et al.

Eur J Cancer. 1995;31A(4):510-5.

PMID:
7576955
3.

Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy.

Kushner BH, Cheung NK, LaQuaglia MP, Ambros PF, Ambros IM, Bonilla MA, Gerald WL, Ladanyi M, Gilbert F, Rosenfield NS, Yeh SD.

J Clin Oncol. 1996 Feb;14(2):373-81.

PMID:
8636746
4.

Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.

Mora J, Cheung NK, Chen L, Qin J, Gerald W.

Cancer. 2001 Jan 15;91(2):435-42.

PMID:
11180092
5.

Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity.

Paulino AC, Mayr NA, Simon JH, Buatti JM.

Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1025-31.

PMID:
11958898
6.

[Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].

Ladenstein R, Ambros PF, Urban C, Ambros IM, Fink FM, Zoubek A, Grienberger H, Schmitt K, Kerbl R, Horcher E, Amann G, Höfler G, Heinzl H, Gadner H, Mutz I.

Klin Padiatr. 1996 Jul-Aug;208(4):210-20. German.

PMID:
8926686
7.

Prognostic significance of DNA di-tetraploidy in neuroblastoma.

Ladenstein R, Ambros IM, Pötschger U, Amann G, Urban C, Fink FM, Schmitt K, Jones R, Slociak M, Schilling F, Ritter J, Berthold F, Gadner H, Ambros PF.

Med Pediatr Oncol. 2001 Jan;36(1):83-92.

PMID:
11464912
8.
9.

Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.

Kramer K, Cheung NK, Gerald WL, LaQuaglia M, Kushner BH, LeClerc JM, LeSauter L, Saragovi HU.

Eur J Cancer. 1997 Oct;33(12):2098-100.

PMID:
9516861
10.

Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.

Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Perez C, Haase GM, Matthay KK.

J Clin Oncol. 2000 Mar;18(6):1260-8.

PMID:
10715296
11.

Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk.

Kushner BH, LaQuaglia MP, Kramer K, Cheung NK.

J Pediatr Hematol Oncol. 2004 Jan;26(1):35-9.

PMID:
14707711
12.

Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.

Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J.

J Clin Oncol. 2000 Feb;18(3):477-86.

PMID:
10653863
13.

Neuroblastoma.

Meir HM, Balawi I, Nayel H, Yousef MK, Badawood S, Al-Mobarak M.

Saudi Med J. 2001 Aug;22(8):674-80.

PMID:
11573111
14.

[Neuroblastoma: biological markers, surgery, and clinical course].

Martínez Ibáñez V, Abad P, Gallego S, Sánchez de Toledo J, Marqués A, Boix Ochoa J.

Cir Pediatr. 2000 Apr;13(2):47-53. Spanish.

PMID:
12602001
15.

The recurrence patterns of stages I, II and III neuroblastoma: experience with 77 relapsing patients.

Berthold F, Hero B, Breu H, Christiansen H, Erttmann R, Gnekow A, Herrmann F, Klingebiel T, Lampert F, Müller-Weihrich S, Weinel P.

Ann Oncol. 1996 Feb;7(2):183-7.

16.

The current contribution of molecular factors to risk estimation in neuroblastoma patients.

Berthold F, Sahin K, Hero B, Christiansen H, Gehring M, Harms D, Horz S, Lampert F, Schwab M, Terpe J.

Eur J Cancer. 1997 Oct;33(12):2092-7.

PMID:
9516860
17.

Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients.

Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK.

Pediatr Blood Cancer. 2006 Mar;46(3):278-84.

PMID:
16124002
18.

Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).

Rubie H, Delattre O, Hartmann O, Combaret V, Michon J, Bénard J, Peyroulet MC, Plantaz D, Coze C, Chastagner P, Baranzelli MC, Frappaz D, Lemerle J, Sommelet D.

Eur J Cancer. 1997 Oct;33(12):1917-22.

PMID:
9516824
19.

Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma.

Mora J, Gerald WL, Cheung NK.

Cancer Lett. 2003 Jul 18;197(1-2):119-24. Review.

PMID:
12880970
20.

Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.

Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN.

J Clin Oncol. 2000 Jan;18(1):18-26.

PMID:
10623689
Items per page

Supplemental Content

Write to the Help Desk